Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-Label Trial to Determine the Safety of PEP on a Skin Graft Donor Site Wound

Next Previous
Trial Profile

A Phase I Open-Label Trial to Determine the Safety of PEP on a Skin Graft Donor Site Wound

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 20 Nov 2023 According to a ROCHESTER, RION media release, the Rochester MN team is actively pursuing exosome-based therapeutics in multiple FDA-authorized clinical trial, including this active trial in wound healing set for estimated completion in Q1 2024.
  • 07 Aug 2023 Status changed from recruiting to active, no longer recruiting.
  • 23 Feb 2023 Number of arms changed from 4 to 3. Experimental: 10% PEP and TISSEEL arm removed from study protocol. Planned number of patients also increased. Eligibility criteria amended to 18 to 75 years.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top